BIOMAT Database Logo BIOMAT Database Logo

Long-term effects of niceritrol on serum lipoprotein(a) and lipids in patients with high levels of lipoprotein(a). 1995

K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Department of Medical Information and Medical Records, Nagoya University Hospital, Japan.

The long-term effects of niceritrol on lipoprotein(a) (Lp[a]), lipids, apolipoproteins, and fibrinogen and fibrinolytic factors were evaluated in 20 outpatients who had serum Lp(a) levels higher than 20 mg/dL. The mean ( +/- SE) levels of Lp(a) decreased from 33.6 +/- 2.3 mg/dL to 23.5 +/- 3.5 mg/dL after 12 months of niceritrol treatment (P < 0.01). Serum levels of triglycerides and apolipoprotein E decreased significantly and high-density lipoprotein cholesterol (HDL-C) increased significantly after 12 months (P < 0.05). There were no significant changes overall in fibrinogen and fibrinolytic factors, although fibrinogen concentrations showed a tendency to decrease with treatment. PAI-1 levels decreased significantly (P < 0.05) after 6 months of niceritrol treatment. A significant correlation of percent reduction between Lp(a) and apolipoprotein B levels (P < 0.01) was observed, suggesting that the Lp(a)-lowering effects of niceritrol may be due to niceritrol inhibition of apolipoprotein B synthesis, the major apolipoprotein of Lp(a). The ability of niceritrol to decrease Lp(a) levels and increase HDL-C levels, together with its tendency to lower fibrinogen levels, may help prevent coronary events in patients with high levels of Lp(a).

UI MeSH Term Description Entries
D006949 Hyperlipidemias Conditions with excess LIPIDS in the blood. Hyperlipemia,Hyperlipidemia,Lipemia,Lipidemia,Hyperlipemias,Lipemias,Lipidemias
D008075 Lipoproteins, HDL A class of lipoproteins of small size (4-13 nm) and dense (greater than 1.063 g/ml) particles. HDL lipoproteins, synthesized in the liver without a lipid core, accumulate cholesterol esters from peripheral tissues and transport them to the liver for re-utilization or elimination from the body (the reverse cholesterol transport). Their major protein component is APOLIPOPROTEIN A-I. HDL also shuttle APOLIPOPROTEINS C and APOLIPOPROTEINS E to and from triglyceride-rich lipoproteins during their catabolism. HDL plasma level has been inversely correlated with the risk of cardiovascular diseases. High Density Lipoprotein,High-Density Lipoprotein,High-Density Lipoproteins,alpha-Lipoprotein,alpha-Lipoproteins,Heavy Lipoproteins,alpha-1 Lipoprotein,Density Lipoprotein, High,HDL Lipoproteins,High Density Lipoproteins,Lipoprotein, High Density,Lipoprotein, High-Density,Lipoproteins, Heavy,Lipoproteins, High-Density,alpha Lipoprotein,alpha Lipoproteins
D008077 Lipoproteins, LDL A class of lipoproteins of small size (18-25 nm) and light (1.019-1.063 g/ml) particles with a core composed mainly of CHOLESTEROL ESTERS and smaller amounts of TRIGLYCERIDES. The surface monolayer consists mostly of PHOSPHOLIPIDS, a single copy of APOLIPOPROTEIN B-100, and free cholesterol molecules. The main LDL function is to transport cholesterol and cholesterol esters to extrahepatic tissues. Low-Density Lipoprotein,Low-Density Lipoproteins,beta-Lipoprotein,beta-Lipoproteins,LDL(1),LDL(2),LDL-1,LDL-2,LDL1,LDL2,Low-Density Lipoprotein 1,Low-Density Lipoprotein 2,LDL Lipoproteins,Lipoprotein, Low-Density,Lipoproteins, Low-Density,Low Density Lipoprotein,Low Density Lipoprotein 1,Low Density Lipoprotein 2,Low Density Lipoproteins,beta Lipoprotein,beta Lipoproteins
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009531 Niceritrol An ester of nicotinic acid that lowers cholesterol and triglycerides in total plasma and in the VLD- and LD-lipoprotein fractions. Pentaerythritol Tetranicotinate,Niceritrol Tetrahydrochloride,Pentaerythritoltetranicotinate,Perycit,Tetrahydrochloride, Niceritrol,Tetranicotinate, Pentaerythritol
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Effects of niceritrol on levels of serum lipids, lipoprotein(a), and fibrinogen in patients with primary hypercholesterolemia.
June 1992, Atherosclerosis,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein (a) and lipids in patients with vascular disease.
January 1996, Journal of atherosclerosis and thrombosis,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
August 1984, Pharmacological research communications,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels.
December 1990, Clinica chimica acta; international journal of clinical chemistry,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Effect of niceritrol on fibrinolysis and lipoprotein (a) levels in patients with coronary artery disease.
February 1996, Coronary artery disease,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Long-term treatment with EPO increases serum levels of high-density lipoprotein in patients with CKD.
August 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
[Changes of serum lipids and high density lipoprotein levels in patients with bronchial asthma].
April 1991, Nihon Kyobu Shikkan Gakkai zasshi,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
[The long-term effects of colestipol hydrochloride on serum and lipoprotein lipids in patients with heterozygous familial hypercholesterolemia (author's transl)].
November 1981, Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.
January 1993, Renal failure,
K Yamauchi, and Y Tanahashi, and M Okada, and J Tsuzuki, and A Sato, and K Abe, and H Inagaki, and H Agetsuma, and R Hattori, and H Izawa
Pentaerythritol tetranicotinate (niceritrol) decreases plasma lipoprotein(a) levels.
April 1997, Metabolism: clinical and experimental,
Copied contents to your clipboard!